» Articles » PMID: 30356316

Seroprevalence of Dengue Virus in Two Districts of Kaohsiung City After the Largest Dengue Outbreak in Taiwan Since World War II

Overview
Date 2018 Oct 26
PMID 30356316
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Dengue virus (DENV) is the leading cause of arboviral diseases in humans worldwide. In this study, we investigated the seroprevalence of DENV infection in two districts of Kaohsiung City, a metropolis in southern Taiwan, where major dengue outbreaks have occurred in the past three decades. We enrolled 1,088 participants from the Sanmin and Nanzih districts after the dengue outbreak of 2015, the largest in Taiwan since World War II, and found an overall DENV seroprevalence of 12.4% (95% confidence interval: 10.5-13.4%) based on the InBios DENV IgG ELISA kit. The ratios of clinically inapparent to symptomatic infections were 2.86 and 4.76 in Sanmin and Nanzih districts, respectively. Consistent with higher case numbers during recent outbreaks, the DENV seroprevalence was higher in Sanmin district (16.4%) than in Nanzih district (6.9%), suggesting district differences in seroprevalence and highlighting the importance of screening the DENV immune status of each individual before using the currently available DENV vaccine, Dengvaxia. In the two districts, the seroprevalence rates increased from 2.1% (in the 30-39-year age group) to 17.1% (60-69) and 50% (70-79). The pattern of a sharp and significant increase in seroprevalence in the 70-79-year age group correlated with a dramatic increase in the proportion of clinically severe DENV infections among total dengue cases in that age group. This differed from observations in the Americas and Southeast Asia and suggested that a large proportion of monotypically immune individuals together with other risk factors may contribute to clinically severe dengue among the elderly in Taiwan.

Citing Articles

Detection of anti-premembrane antibody as a specific marker of four flavivirus serocomplexes and its application to serosurveillance in endemic regions.

Chen G, Dai Y, Hsieh S, Tsai J, Sy A, Jiz M Emerg Microbes Infect. 2024; 13(1):2301666.

PMID: 38163752 PMC: 10810658. DOI: 10.1080/22221751.2023.2301666.


Chikungunya virus antepartum transmission and abnormal infant outcomes in a cohort of pregnant women in Nigeria.

Sagay A, Hsieh S, Dai Y, Chang C, Ogwuche J, Ige O Int J Infect Dis. 2023; 139:92-100.

PMID: 38056689 PMC: 10843725. DOI: 10.1016/j.ijid.2023.11.036.


Dengue virus serotype did not contribute to clinical severity or mortality in Taiwan's largest dengue outbreak in 2015.

Tsai J, Chang K, Chen C, Liao C, Chen L, Tsai Y Eur J Med Res. 2023; 28(1):482.

PMID: 37932817 PMC: 10626727. DOI: 10.1186/s40001-023-01454-3.


Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines.

Dai Y, Sy A, Jiz M, Tsai J, Bato J, Quinones M Front Immunol. 2023; 14:1202055.

PMID: 37554332 PMC: 10405517. DOI: 10.3389/fimmu.2023.1202055.


Comparing the performance of dengue virus IgG and IgG-capture enzyme-linked immunosorbent assays in seroprevalence study.

Tsai J, Tsai C, Lin P, Chen C, Tsai W, Dai Y BMC Infect Dis. 2023; 23(1):301.

PMID: 37158835 PMC: 10165301. DOI: 10.1186/s12879-023-08307-8.


References
1.
Chang K, Huang C, Lee I, Lu P, Lin C, Chen T . Differences in Mortality and Clinical Manifestations of Dengue Hemorrhagic Fever in Taiwan in Different Years: A Comparison for Cases in 2014 and 2015 Epidemics. Am J Trop Med Hyg. 2017; 97(2):361-368. PMC: 5544090. DOI: 10.4269/ajtmh.16-1018. View

2.
Paldanius M, Bloigu A, Leinonen M, Saikku P . Measurement of Chlamydia pneumoniae-specific immunoglobulin A (IgA) antibodies by the microimmunofluorescence (MIF) method: comparison of seven fluorescein-labeled anti-human IgA conjugates in an in-house MIF test using one commercial MIF and one.... Clin Diagn Lab Immunol. 2003; 10(1):8-12. PMC: 145278. DOI: 10.1128/cdli.10.1.8-12.2003. View

3.
Schwartz L, Halloran M, Durbin A, Longini Jr I . The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine. 2015; 33(29):3293-8. PMC: 4470297. DOI: 10.1016/j.vaccine.2015.05.010. View

4.
Cavalcanti L, Vilar D, Souza-Santos R, Teixeira M . Change in age pattern of persons with dengue, northeastern Brazil. Emerg Infect Dis. 2011; 17(1):132-4. PMC: 3204623. DOI: 10.3201/eid1701.100321. View

5.
Hadinegoro S, Arredondo-Garcia J, Capeding M, Deseda C, Chotpitayasunondh T, Dietze R . Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015; 373(13):1195-206. DOI: 10.1056/NEJMoa1506223. View